中文 | English
Return
Total: 784 , 1/79
Show Home Prev Next End page: GO
MeSH:(In Situ Hybridization)

2.Clinical use cytogenetic karyotyping , fluorescence in situ hybridization , and primed in situ labelling in prenatal diagnosis.

Young Ju KIM ; Bock Hi WOO ; Hun Jin YANG ; Mi Young PARK ; Young Hi LEE ; Jung Ja AHN

Korean Journal of Obstetrics and Gynecology 1999;42(1):72-79

5.Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma.

Sun Min LIM ; Jeong Eun YOO ; Kiat Hon LIM ; David Wai MENG TAI ; Byoung Chul CHO ; Young Nyun PARK

Cancer Research and Treatment 2017;49(1):185-192

6.Diagnostic Value of MDM2 and DDIT3 Fluorescence In Situ Hybridization in Liposarcoma Classification: A Single-Institution Experience

Junhun CHO ; Seung Eun LEE ; Yoon La CHOI

Korean Journal of Pathology 2012;46(2):115-122

7.Duplication of intrachromosomal insertion segments 4q32-->q35 confirmed by comparative genomic hybridization and fluorescent in situ hybridization.

Jin Woo KIM ; Ju Yeon PARK ; Ah Rum OH ; Eun Young CHOI ; Hyun Mee RYU ; Inn Soo KANG ; Mi Kyoung KOONG ; So Yeon PARK

Clinical and Experimental Reproductive Medicine 2011;38(4):238-241

8.A Single Institute's Experience of Standardization for the HER2 Status by Fluorescence in situ Hybridization and Immunohistochemistry on a Primary Breast Cancer Tissue Microarray.

Kyeongmee PARK ; Sehwan HAN

Journal of Korean Breast Cancer Society 2004;7(1):27-31

10.Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer.

Kyeongmee PARK ; Sehwan HAN ; Jung Yeon KIM ; Hyun Jung KIM ; Ji Eun KWON ; Geumhee GWAK

Journal of Breast Cancer 2011;14(4):276-282

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 784 , 1/79 Show Home Prev Next End page: GO